Planned clinical trials include a phase II study, utilising the EZH2 inhibitor tazemetostat in combination with immune checkpoint inhibitor durvalumab and will include a cohort of STS patients (NCT04705818). This evidence concerns the gene EZH2 and telomere syndrome.